Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

2017303 citationsJournal Articlegold Open Access

Authors

Bert H. O’Neil · Indiana University – Purdue University Indianapolis

John M. Wallmark · Maryland Oncology Hematology

David Lorente · Royal Marsden NHS Foundation Trust

Élena Elez · Vall d'Hebron Hospital Universitari

Judith Raimbourg · Institut de Cancérologie de l'Ouest

Carlos Gomez‐Roca · Institut Claudius Regaud

Samuel Ejadi

Abstract

Pembrolizumab demonstrated a favorable safety profile in advanced PD-L1-positive CRC. Antitumor activity was observed in a single patient with MSI-high CRC, warranting further evaluation in this patient population. (Clinicaltrials.gov registration: NCT02054806).

Topics & Keywords

Cancer Immunotherapy and Biomarkers Colorectal Cancer Treatments and Studies Colorectal and Anal Carcinomas

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: PLoS ONE

Volume 12, Issue 12, pp. e0189848-e0189848

DOI: 10.1371/journal.pone.0189848

Field-Weighted Citation Impact: 9.65